Background Image
Table of Contents Table of Contents
Previous Page  168 / 708 Next Page
Information
Show Menu
Previous Page 168 / 708 Next Page
Page Background

22

I’m adding three funds to the Morningstar

500

.

Causeway Emerging Markets

CEMVX

, with a Morn-

ingstar Analyst Rating of Bronze, is showing that

quantitative approaches canwork just aswell in emerging

markets as in developed markets. Management

believes the quantitative approach enables it to cast a

wider net than would otherwise be possible using

analysts for fundamental research. It combines value

and momentum models along with top-down models

and risk-management models to build the portfolio. The

resulting portfolio has about

100

stocks and has a

distinct value tilt.

The top-down and risk-management models are crucial

because big macroeconomic and currency move-

ments have overwhelmed individual company funda-

mentals for much of the past decade. In fact, the

results have been pretty strong in a variety of markets.

The fund is run by Causeway’s quantitative team, so

it does not have the same management as

Causeway

International Value

CIVVX

. See Page

5

for details.

Two Multialternative Funds Join

Last month, we wrote about the landscape in the

world of multialternative funds. This month, I’m

adding two of the funds profiled in that article. Both

are available in most No Transaction Fee platforms.

Natixis ASG Global Alternatives

GAFAX

aims to track

a hedge fund index by using futures contracts to

mimic what hedge funds are doing. It does so using a

targeted

8%

volatility level and using a stop-loss rule

to curb the downside. By trying to replicate hedge fund

performance rather than actually running a hedge-

fund-like strategy, the fund can save some money on

investment professionals and pricey subadvisors.

Thus, the fund’s fees are cheaper than most in an admit-

tedly pricey group. See the facing page for more.

Litman Gregory Masters Alternative Strategies

MASNX

is a fairly bold alternative fund with a well-known

lineup. The Bronze-rated fund is split between a

bond side and a stock side. The bond side includes a

global unconstrained-bond strategy run by Loomis

Sayles and an aggressive mortgage sleeve run by Double-

Line Capital. The other half of the fund is run by First

Pacific Advisors, Water Island Capital (merger arbitrage),

and Passport Capital (long-short). See Page

6

for details.

Three Go Out

Artisan Small Cap Value

ARTVX

is being merged into

Artisan Mid Cap Value

ARTQX

, so it’s going out.

Oppenheimer Gold & Special Minerals

OPGSX

has

been dropped from coverage.

Finally, Neutral-rated

Appleseed

APPLX

has less than

$200

million and is a logical candidate to drop.

K

What is Morningstar

FundInvestor

500

?

The Morningstar FundInvestor

500

features the industry’s

best and most notable funds.

Use the list to get new in-

vestment ideas and track the

funds you already own.

FundInvestor

subscribers have

access to one-page monthly

reports on all 500 funds on

mfi.morningstar.com. Just

type in the name or ticker of

the fund in the search box.

Alternative Funds Make a Splash

Changes to the 500

|

Russel Kinnel

Summary of Changes

Add

Drop

Causeway Emerging Markets

Appleseed

Litman Gregory Masters Alt Strats

Artisan Small Cap Value

Natixis ASG Global Alternatives

Oppenheimer Gold & Special Min

Rating Change (Upgrade)

From

To

Baird Core Plus Bond

´ •

Vanguard Strategic Equity

‰ ´

Wasatch Core Growth

• Œ

Rating Change (Downgrades)

From

To

Amana Growth

• ´

Amana Income

• ´

Artisan Small Cap Value

´ ‰

Longleaf Partners

• ‰

Longleaf Partners Small-Cap

Œ •

Sequoia

Œ ´

Virtus Emerging Markets Opportunities

• ´

Virtus Foreign Opportunities

• ´

Rating Change (Under Review)

From

To

Manning & Napier Pro-Blend Cnsrv Term

´ ˆ

Manning & Napier Pro-Blend Extnd Term

´ ˆ

Manning & Napier Pro-Blend Max Term

´ ˆ

New

Ratings

To

Baird Aggregate Bond

Causeway Emerging Markets

´

FMI International

T. Rowe Price Global Technology

´

T. Rowe Price Health Sciences